Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the ...

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...

OPEN The FTSE 100 was expected to open 19.9 points lower on Friday after wrapping up the previous session 0.55% higher at 8,823.20.

AstraZeneca Pharma India shares saw a rise after Imfinzi got approval for expanded use. The CDSCO approved it as a first-line ...

Imfinzi is approved in the US and other countries for patients with muscle-invasive bladder cancer (MIBC) based on results from the NIAGARA Phase III trial and continues to be investigated across ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

AstraZeneca Pharma India Limited on Tuesday, July 1, 2025, received approval from the Central Drugs Standard Control ...